

1 **Safety of Repeated Low-Level Red-Light Therapy for Myopia: A Systematic**
2 **Review**

3

4 **Running Title:** Safety of repeated low-level red-light therapy

5

6 **Authors**

7 Yanping Chen, MD^{1*}, Shida Chen, MD, PhD^{1*}, Ruilin Xiong, MD, PhD^{1*}, Shaopeng

8 Yang, MD¹, Riqian Liu, MD¹, Ziyu Zhu, MBBS¹, Kaidi Xiang, MD^{2,3}, Nathan

9 Congdon, MD, MPH^{1,4,5†}, Wei Wang, MD, PhD^{1†}

10

11 **Affiliations**

12 1. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun
13 Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and
14 Visual Science, Guangdong Provincial Clinical Research Center for Ocular
15 Diseases, Guangzhou, Guangdong, China.

16 2. Department of Clinical Research, Shanghai Eye Disease Prevention and
17 Treatment Center, Shanghai Eye Hospital, Shanghai Vision Health Center and
18 Shanghai Children Myopia Institute, Shanghai, China.

19 3. Department of Ophthalmology, Shanghai General Hospital (Shanghai First
20 People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai,
21 China; National Clinical Research Center for Eye Diseases; Shanghai Clinical
22 Research Center for Eye Diseases; Shanghai Key Clinical Specialty; Shanghai
23 Key Laboratory of Ocular Fundus Diseases; Shanghai Engineering Center for
24 Visual Science and Photomedicine; Shanghai Engineering Center for Precise
25 Diagnosis and Treatment of Eye Diseases, Shanghai Eye Research Institute,
26 Shanghai, China.

27 4. Centre for Public Health, Queen's University Belfast, Belfast, United Kingdom.

28 5. Orbis International, New York, New York, United States of America.

29 *Co-first authors. †Co-corresponding authors.

30

31 **Corresponding Author**

32 Wei Wang, MD PhD, Zhongshan Ophthalmic Center, State Key Laboratory of
33 Ophthalmology, Sun Yat-sen University, Guangzhou, China.

34 Email: wangwei@gzzoc.com | ORCID: <https://orcid.org/0000-0002-5273-3332>

35

36 Nathan Congdon, MD, MPH, Zhongshan Ophthalmic Center, State Key Laboratory of
37 Ophthalmology, Sun Yat-sen University, Guangzhou, China; Centre for Public Health,
38 Queen's University Belfast, Belfast, United Kingdom; Orbis International, New York,
39 New York, United States of America.

40 Email: ncongdon1@gmail.com | ORCID: <https://orcid.org/0000-0001-9866-3416>

41

42 **Financial Support**

43 This research was supported by the National Natural Science Foundation of China
44 (82371086). The sponsors or funding organizations had no roles in the design or
45 conduct of this research.

46

47 **Conflicts of Interests**

48 All authors declare no competing interests.

49

50 **Word Count:** [Abstract: 343 / Text: 3718]

51 **Tables: 4**

52 **Figures: 2**

53 **Supplementary Tables: 3**

54

55 **Abbreviations and Acronyms:**

56 RLRL = repeated low-level red-light; OCT = optical coherence tomography; CI =
57 confidence interval; IMI = International Myopia Institute; RCT = randomized
58 controlled trial; SER = spherical equivalent refraction; AL = axial length; NNH =
59 number needed to harm; NNT = number needed to treat; SVS = single-vision
60 spectacles; BCVA = best-corrected visual acuity.

62 **Abstract**

63 **Topic:** Existing evidence for the safety of repeated low-level red-light (RLRL)
64 therapy for myopia control.

65 **Clinical relevance:** Recent trials show RLRL therapy is effective in the prevention
66 and control of myopia. Establishing its safety profile is necessary prior to widespread
67 clinical implementation.

68 **Methods:** We conducted a systematic review (International Prospective Register of
69 Systematic Reviews, CRD42024516676) of articles across seven databases from
70 inception through February 10, 2024, with keywords related to myopia and RLRL
71 therapy. Pooled safety outcomes and risk-to-benefit ratios were reported, and
72 incidence of side effects was compared with other anti-myopia interventions. Quality
73 appraisal was performed using the Cochrane Risk of Bias Tool.

74 **Results:** Among 689 screened articles, 20 studies (2.90%; eleven randomized
75 controlled trials, four non-randomized controlled trials, one post-trial study, one
76 single-arm study, one retrospective study and two case reports of identical patient.;
77 median duration 9 months, longest 24 months) were analysed, encompassing 2,380
78 participants aged 3-18 years and 1,436 individuals undergoing RLRL therapy. Two
79 case reports described an identical patient with reversible decline in visual acuity and
80 optical coherence tomography (OCT) abnormalities, completely resolved 4 months
81 after treatment cessation. No cases of permanent vision loss were reported. Temporary
82 afterimage was the most common ocular symptom following treatment, resolving
83 within 6 minutes in reported studies. The number needed to harm outweighed the
84 number needed to treat by a ratio of 12.7-21.4 for a person with -3D to -8D myopia
85 treated with RLRL therapy. Incidence of side effects from RLRL was 0.088 per 100
86 patient-years (95% confidence interval [CI], 0.02-0.50), comparable to spectacles
87 designed for myopia reduction (0.22; 95% CI, 0.09-0.51; P=0.385), and significantly
88 lower than for low-dose atropine (7.32; 95% CI, 6.65-8.05; P<0.001), orthokeratology
89 (20.6; 95% CI, 16.7-25.0; P<0.001), other anti-myopia contact lens (19.3; 95% CI,
90 17.6-21.1; P<0.001).

91 **Conclusion:** No irreversible visual function loss or ocular structural damage was

92 identified with RLRL. Fundus photography and OCT before and during therapy,
93 alongside home monitoring of visual acuity and duration of afterimages, are necessary
94 to identify side effects. Further adequately-powered studies of longer duration are
95 needed to evaluate long-term safety of RLRL.

96

97 **Keywords:** Refractive error, myopia prevention, repeated low-level red-light, safety,
98 risk-to-benefit

99

100 **Introduction**

101 Myopia is the most common ocular disorder of childhood and adolescence. Without
102 effective intervention measures, it is estimated that approximately 50% of the global
103 population will be affected by 2050.¹ The rising prevalence of myopia, along with
104 earlier onset, increases the risk of high myopia, which may be associated with
105 irreversible, sight-threatening complications such as myopic maculopathy, glaucoma
106 and retinal detachment.²⁻⁴ Therefore, prevention and control of myopia have become
107 important public health challenges.

108

109 Repeated low-level red-light (RLRL) therapy, highlighted in the latest 2023 Digest of
110 the International Myopia Institute (IMI), has emerged as a novel approach to myopia
111 prevention.⁵ RLRL therapy involves locally irradiating the retina with low-level red
112 light (approximately 1600 lux). It falls under Group 1 of the ANSI Z80.36-2021
113 standard,⁶ ensuring its safety for clinical ophthalmic applications. Unlike traditional
114 therapeutic lasers such as panretinal photocoagulation, which rely on thermal effects
115 generated through transpupillary energy ranging from 200-250 mW passing through
116 the pupil, RLRL uses a much lower energy level of 0.29 mW, avoiding any thermal
117 effects. Its therapeutic impact is postulated to rely on photobiomodulation (PBM)
118 secondary to the laser's energy, potentially leading to thickening of the choroidal
119 layer.⁷

120

121 Growing trial evidence supports the effectiveness of RLRL therapy in reducing
122 myopia progression. The first multicenter randomized controlled trial (RCT) in China
123 demonstrated in 2019 that home-based RLRL therapy, administered for 3 minutes
124 twice daily for 5 days a week, significantly reduced axial elongation by 69.4% and
125 refractive progression by 76.6% among school-aged children.⁸ Subsequent clinical
126 trials have consistently confirmed these findings.⁹⁻¹¹ Recently, a meta-analysis
127 incorporating 13 studies comprising 8 RCTs, 3 non-randomized controlled trials and 2
128 cohort studies, and involving a total of 1857 children and adolescents, confirmed the
129 efficacy of RLRL therapy.¹² Six-month weighted differences in spherical equivalent

130 refraction (SER) and axial length (AL) were 0.68 diopters (D) and 0.35 mm
131 respectively between the RLRL treatment group and controls. However, published
132 studies have predominantly focused on efficacy outcomes, with limited reporting of
133 the safety and side effects of RLRL therapy.

134
135 To address this important knowledge gap, we systematically reviewed the safety
136 profiles and risk-to-benefit ratio associated with RLRL treatment for myopia
137 prevention and control. The aim of this study is to provide insights to help both
138 clinicians and program designers optimize use of RLRL therapy, ensuring its safe and
139 effective integration into myopia management.

140

141 **Methods**

142 This review was registered prospectively on the International Prospective Register of
143 Systematic Reviews database (available from
144 https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024516676) and
145 is reported in accordance with the Preferred Reporting Items for Systematic Reviews
146 and Meta-Analyses (PRISMA) statement.¹³ All research adhered to the tenets of the
147 Declaration of Helsinki. Individual patient-level consent was not required, nor was
148 ethical review.

149

150 **Eligibility Criteria**

151 We included clinical studies of RLRL therapy designed to prevent myopia or delay its
152 progression. Studies were selected according to the following criteria: (1) Participants
153 were younger than 18 years with myopia or premyopia; (2) RLRL therapy was used in
154 at least one arm or by all participants; (3) Reporting of at least 1 safety outcome,
155 including visual function, ocular structural assessment, or adverse events; (4) All
156 study types except literature reviews, in order to capture as many reported safety
157 profiles and side effects as possible. We excluded studies on non-human subjects,
158 those enrolling participants with secondary myopia, without safety data, and those
159 merely describing treatments combined with RLRL therapy or involving red light

160 flicker rather than continuous administration.

161

162 **Search Strategy**

163 A comprehensive search of the peer-reviewed literature was conducted across seven
164 databases, including PubMed, Embase, Web of Science, Cochrane Library, Scopus,
165 the Chinese databases China National Knowledge Infrastructure and VIP Information
166 Database, from their dates of inception through 10 February 2024. We used a
167 combination of key words related to myopia and RLRL therapy, imposing no
168 language restrictions. To ensure thorough coverage, we also scrutinized relevant
169 reviews and all references cited by eligible studies for additional pertinent
170 publications. The full search strategy is detailed in **Table S1**.

171

172 **Study Selection**

173 Citations retrieved from electronic databases were compiled into an EndNote library
174 by one author (Y.C.). After the removal of duplicates, two reviewers (Y.C., R.X.)
175 independently screened titles and abstracts to assess initial eligibility. Reviewers then
176 checked the full text for potentially eligible studies to determine their final inclusion
177 or exclusion. The primary reason for exclusion was documented at the full text
178 screening stage. Any discrepancies between reviewers were resolved through
179 discussion or by consulting a third researcher if necessary (W.W.).

180

181 **Data Collection and Risk of Bias Assessment**

182 Data were extracted independently by two reviewers (Y.C., R.X.)
183 and were entered into an Excel spreadsheet (version 2022, Microsoft Corporation,
184 Redmond, USA). For each included study, the extracted information consisted of
185 author's name, year of publication, study design, country or area, specification of the
186 red light device (device name, manufacturer, wavelength and power), treatment
187 regimen, sample size, follow-up duration, age, sex, baseline SER, baseline AL, safety
188 outcomes, and participation completion rate. For the safety outcomes, we documented
189 all safety data reported throughout the selected studies. Two reviewers (Y.C., S.Y.)

190 independently appraised articles for systematic bias using the Cochrane Risk of Bias
191 Tool.¹⁴

192

193 **Data Synthesis and Analysis**

194 Given the heterogeneous reporting of safety outcomes among the included studies, it
195 was not feasible to conduct a pooled meta-analysis.¹⁵ Instead, we performed a
196 risk-to-benefit analysis according to the model described by Bullimore to assess
197 whether the potential benefits of reducing myopia progression of 1D with RLRL
198 therapy outweigh the potential risks associated with the treatment.¹⁶ The revised
199 Bullimore's model is based on three assumptions: 1) Every patient undergoing myopia
200 control will use RLRL for a 5-year treatment period. Since there's lack of long-term
201 efficacy of RLRL therapy, the selection of five years facilitates the conservative
202 estimation of the effect of controlling myopia progression within 1D as per previous
203 review.¹⁷ 2) Serious adverse events, if they occur, may happen at a mean age of 12
204 years during this five-year treatment period.¹⁶ 3) Based on the estimated mean life
205 expectancy of 77 years in China (<https://data.who.int>), any adverse event resulting in
206 immediate visual impairment will lead to visual impairment for a duration of 65 years.
207 The annual incidence rate of vision loss was calculated using the number of children
208 experiencing visual impairment from RLRL as the numerator and the estimated total
209 number of patient-years in reported clinical RLRL studies with safety outcomes as the
210 denominator. The absolute risk increase (ARI) of vision loss years was estimated by
211 multiplying the annual incidence of vision loss per 10,000 patients by the assumed
212 duration of visual impairment, which is 65 years. The number needed to harm (NNH)
213 was then calculated as the reciprocal of ARI. This metric indicates the number of
214 patients who need to be treated to induce one case of visual impairment.

215

216 According to Bullimore's model, the benefit of preventing visual impairment from
217 blinding myopic related complications by 1D was regardless of the treatment. The
218 average duration of visual impairment that a patient is likely to experience over their
219 lifetime at myopia ranging from -3D to -8D was estimated.¹⁶ For instance, a patient

220 with -3D myopia is expected to experience an average of 4.42 years of visual
221 impairment (mild visual impairment as US definition of 20/40) while a -4D person
222 will experience 5.25 years of visual impairment. Thus, the benefit of slowing myopia
223 progression by 1D is quantified by the difference in years of visual impairment,
224 amounting to a prevention of 0.84 years of visual impairment if myopia control
225 interventions in an individual potentially reaching -4D myopia result in achieving
226 only -3D. The values of years of visual impairment prevented by 1D reduction ranges
227 from 0.74 to 1.22 for -3D to -8D. The number needed to treat (NNT) was evaluated in
228 Bullimore's model to prevent 1-year (NNT range, 0.82-1.38) and 5-year (NNT range,
229 4.11-6.75) visual impairment.¹⁶ Furtherly, we calculated the NNH/NNT ratio for
230 RLRL therapy in patients with myopia degrees ranging from -3D to -8D.

231

232 Additionally, we conducted a systematic comparison of the incidence of side effects
233 between RLRL therapy and other anti-myopia interventions. Our approach involved a
234 systematic search of all eligible peer-reviewed RCTs that included myopic or
235 premyopic participants younger than 18 years, had at least a one-year follow-up
236 period, and investigated interventions including low-dose atropine, orthokeratology,
237 other contact lenses, and spectacles. For spectacles, we included bifocal lens,
238 progressive addition spectacles, aspherical lenslets and peripheral defocus spectacles
239 as spectacles designed for myopia reduction since their incidence rates of adverse
240 events were similar. Adverse events of other interventions were counted as the number
241 of events reported in published RCTs. The crude incidence of adverse events was
242 computed per 100 patient-years of intervention, with 95% confidence intervals (CIs)
243 calculated using the Wilson method.^{18,19} A two-sided p value <0.05 was defined as
244 statistically significant. All data analyses were performed using Stata (version 17.0,
245 StataCorp, College Station, Texas, USA).

246

247 **Results**

248 **Study Selection**

249 Of the 689 references retrieved, 39 full-text articles (5.66%) were reviewed, and 20

250 studies (2.90%) were identified as eligible for systematic review (**Figure 1**). The
251 primary reason for exclusion during the full-text review process was the absence of
252 reported safety outcomes (n=14, 73.7%).^{7, 20-32}

253

254 **Characteristics of Included Studies**

255 The 20 studies comprised eleven RCTs,^{8, 10, 11, 33-40} four non-randomized controlled
256 trials,⁴¹⁻⁴⁴ one post-trial study,⁹ one single-arm study,⁴⁵ one retrospective study⁴⁶ and
257 two case reports of identical patient.^{47, 48} Fifteen studies evaluated the safety and
258 efficacy of RLRL therapy compared to controls, eleven with single-vision spectacles
259 (SVS),^{8, 10, 33, 35-37, 39-43} one with a sham device,¹¹ one with 0.01% atropine,³⁴ and one
260 with orthokeratology, SVS, and combination treatment of orthokeratology and
261 RLRL.⁴⁴ One study compared the safety and efficacy between RLRL devices with
262 different powers and SVS.³⁸ Two case reports described the identical individual case
263 with different details;^{47, 48} thus we comprehensively reviewed the two reports but only
264 included as one participant in the systematic review. These studies included a total of
265 2,380 participants aged 3-18 years presenting at baseline with myopia (cycloplegic
266 SER -0.50 to -9.00D) or premyopia (cycloplegic SER -0.50 to +0.75D), among them
267 1,436 subjects undergoing RLRL therapy. The median follow-up duration was 9
268 months, with an interquartile range of 6-12 months, and a longest follow-up period of
269 24 months. All studies reported a participant completion rate of over 50%, were
270 conducted in China, and published between 2021 and 2024. (**Table 1**). The risk of bias
271 assessment is shown in **Figure 2**.

272

273 The specifications of RLRL therapy and treatment regimens across the included
274 studies are summarized in **Table S2**. Four types of RLRL devices were utilized,
275 including Eyerising (Jiangsu, China; n=14 studies; 650±10 nm, 2.00±0.50 mW),^{8-11, 33,}
276 ^{34, 40-42, 44-48} LD-A (Jilin, China; n=2 studies; 635 nm, 0.35±0.02 mW),^{35, 37} YF020A
277 (Hunan, China; n=3 studies; 650 nm, no specified power),^{36, 39, 43} and sky-n1201
278 (Beijing, China; n=1 study; 650 nm, with variable outputs of 0.37±0.02 mW, 0.60±0.2
279 mW, and 1.20 mW).³⁸ All studies adhered to a uniform daily RLRL treatment protocol,

280 consisting of two daily 3-minute sessions, with a minimum interval of 4 hours
281 between sessions. Six studies implemented a 5-day per week regimen,^{8-10, 41, 43, 46}
282 while the remaining 14 studies provided treatment 7 days per week.^{11, 33-40, 42, 44, 45, 47, 48}

283

284 **Safety Profiles of RLRL Therapy**

285 **Table 2** presents the safety outcomes reported among participants undergoing RLRL
286 therapy. In these studies, visual function was assessed using best-corrected visual
287 acuity (BCVA) or multifocal electroretinogram, while ocular structures were
288 evaluated with optical coherence tomography (OCT), fundus photography, or
289 slit-lamp microscopy. Among 529 children assessed for visual function, 528 (99.8%)
290 either maintained a BCVA of $\geq 20/25$ or experienced no decline at follow-up visits
291 compared to baseline. OCT identified no structural damage in 624 (99.8%) of the 625
292 participants with such data.

293

294 Two case reports described the same twelve-year-old girl who experienced a two-line
295 decline in binocular BCVA after five months of RLRL therapy.^{47, 48} The child was
296 highly myopic prior to initiating RLRL, with SER of -6.75D in the right eye and
297 -6.25D in the left eye, and BCVA of 20/25 at the point of initiation. Due to repeated
298 inflammation from orthokeratology, the subject had been switched to RLRL for
299 managing myopia. After three months of RLRL treatment, the BCVA improved to
300 20/20. After five months for RLRL treatment, the child showed the binocular BCVA
301 decrease from 20/20 to 20/30 with prolonged afterimages occasionally exceeding 8
302 minutes. Multifocal electroretinogram indicated moderately and mildly decreased
303 response in the macula and paramacular respectively. OCT images showed bilateral
304 disruption of the foveal ellipsoid zone and discontinuity of the interdigitation zone.
305 Fundus photographs revealed bilaterally darkened foveae with a hypoautofluorescent
306 plaque in autofluorescence images. The bilateral outer retinal damage showed partial
307 recovery, with an improvement in binocular BCVA to 20/25, three months after
308 discontinuation of RLRL therapy. Complete recovery of bilateral outer retinal damage
309 was observed four months after discontinuing RLRL therapy.

310

311 Nineteen studies reported on ocular adverse events. In one study with 20 participants
312 treated with RLRL, afterimages lasting a mean of 3.2 ± 1.2 minutes were documented
313 without any objective ocular abnormalities.³⁷ One trial reported afterimage as the
314 most common phenomenon post light therapy, which can be alleviated by a short
315 period of eye-closing and rest.⁴¹ Another study demonstrated no afterimages longer
316 than 6 minutes after 1-year RLRL treatment within 126 premyopic children.¹⁰ One
317 individual experienced dizziness following the red-light therapy; however, this
318 symptom resolved within a few minutes and persisted during the immediate
319 post-treatment period for only a few days.³⁴ Aside from the aforementioned case
320 report,^{47, 48} no other included participants experienced vision loss of ≥ 2 lines, scotoma
321 or treatment-related adverse events post-therapy.

322

323 **Risk-to-benefit Analysis**

324 The sole event of temporary vision loss described in the case reports is considered as
325 the numerator,^{47, 48} and the denominator is a conservative estimate of the total number
326 of participants in reported clinical RLRL studies with safety outcomes. The annual
327 incidence of vision loss from RLRL therapy was estimated as 8.77 per 10,000
328 patient-years. **Table 3** shows the NNH and NNH/NNT estimates for 1 year and 5
329 years visual impairment associated with RLRL based on Bullimore's model. A total of
330 17.5 individuals have to implement RLRL therapy for 5 years to result in 1-year of
331 visual impairment, while 87.7 patients have to use it to result in 5-year of visual
332 impairment.

333

334 From Bullimore's assessment, controlling myopia by 1D prevents between 0.74 and
335 1.22 years of visual impairment due to myopic complications across myopia levels of
336 -3D to -8D.¹⁶ This benefit outweighs the risk of visual impairment years from RLRL
337 treatment, which is 570 per 10,000 patients, or 0.057 year per patient. On the other
338 hand, the NNH outweighs the NNT by a ratio of 12.7-21.4 for a person with -3D to
339 -8D myopia treated with RLRL therapy.

340

341 **Comparison with Other Interventions**

342 We further compared the incidence rates of ocular adverse events between RLRL and
343 other myopia interventions. The characteristics and adverse events of other treatments
344 reported in RCTs lasting at least 1 year are displayed in **Table S3**. The side effect
345 incidence of RLRL therapy is 0.088 per 100 patient-years (95% confidence interval
346 [CI], 0.02-0.50), which is comparable to spectacles designed for myopia reduction
347 (0.22 per 100 patient-years; 95% CI, 0.09-0.51; P=0.385),⁴⁹⁻⁵⁹ and significantly lower
348 than for low-dose atropine (7.32 per 100 patient-years; 95% CI, 6.65-8.05;
349 P<0.001),⁶⁰⁻⁷⁸ orthokeratology (20.6 per 100 patient-years; 95% CI, 16.7-25.0;
350 P<0.001)^{77, 79-84} and other anti-myopia contact lens (19.3 per 100 patient-years; 95%
351 CI, 17.6-21.1; P<0.001)⁸⁵⁻⁹⁰ (**Table 4**).

352

353 **Discussion**

354 The results of the systematic review indicated that no visual function loss or ocular
355 structural change with irreversible damage was identified with RLRL therapy. An
356 afterimage was the most common ocular symptom following treatment, with a
357 resolution time of less than 6 minutes reported in two clinical trials. This phenomenon,
358 induced by prior adaptation to a visual stimulus, is believed to be due to the natural
359 bleaching of photochemical pigments or neural adaptation in the retina. Participants
360 with an afterimage duration exceeding 6 minutes were considered clinically too
361 sensitive to the light stimulus.^{10, 91} Among dozens of published studies, only two
362 reported on a single case of a reversible decline in visual function and discontinuity of
363 the foveal ellipsoid and interdigitation zones in an identical girl, with complete
364 recovery after four months of treatment cessation. A risk-to-benefit analysis
365 emphasized that the benefit of reducing visual impairment outweighed the potential
366 risks associated with RLRL treatment. The incidence rate of side effects from RLRL
367 therapy was comparable to that of spectacles wearing, and was lower than that of
368 other therapies.

369

370 Of note, two case reports, both describing on complications of the same child
371 following RLRL therapy offers valuable clinical data and serves as a reference point
372 for RLRL's clinical application.^{47, 48} Given the rarity of this adverse event, it might be
373 secondary to specific individual differences, where the patient may be especially
374 responsive to light therapy. Such individual variability may render the retina more
375 sensitive to light and prone to phototoxicity. It is important to note that the patient was
376 highly myopic, a condition that often involves inherent issues with the retinal
377 structure of the fundus. From the addition information provided by the authors of one
378 case report,⁴⁸ this child experienced significant myopia regression (cycloplegic SER
379 from -6.75D at baseline to -4.50D after 1 month in the right eye; from -6.25D at
380 baseline to -4.50D after 1 month in the left eye) following RLRL treatment. The dark
381 choroid shown in the OCT image post RLRL has been suggested in a non
382 peer-reviewed letter to the editor regarding the case written by experts in inherited
383 retinal disease to represent Stargardt's disease
384 (<https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2805391>).

385
386 Although the incidence of such adverse events is extremely low, identifying such
387 super-responders to RLRL therapy is still important. From this case, possible
388 characteristics of super-responders include a significant treatment effect, a marked
389 SER regression or AL shortening and an afterimage duration exceeding 6 minutes in
390 response to light exposure. It is crucial for clinicians and parents to closely monitor
391 subjects with these characteristics, as any decrease in visual acuity while wearing
392 glasses may suggest the development of such complications, which can then be
393 further detected and characterized through OCT examination. Importantly, these
394 complications are reversible as after stopping treatment for 4 months, the visual
395 function and ocular structures changes returned to normal. Meticulous supervision is
396 thus necessary throughout the treatment process to ensure safe implementation of
397 RLRL. Appropriate actions include documentation of the retina through fundus
398 photography and OCT before starting treatment and at each routine examination,
399 tracking visual acuity, and recording the duration of any afterimages.⁹²

400

401 A comprehensive risk-to-benefit assessment of myopia treatments should consider
402 various factors, including the intervention effectiveness in slowing myopia
403 progression, the risk of myopia-related visual impairment, the degree of myopia
404 treated, and the specific risks associated with each intervention. From this
405 risk-to-benefit analysis, the risk of vision loss associated with RLRL treatment is seen
406 to be counterbalanced by its benefits in preventing myopia-related visual impairment
407 with a NNH/NNT ratio of 12.7 to 21.4. Previous studies have reported a NNH/NNT
408 ratio ranging from 5.43 for -3D to 9.15 for -8D for overnight contact lens wearing.^{16,}
409 ⁹³

410

411 Additionally, nearly all interventions for myopia control are associated with some
412 side effects and complications. Our systematic review summarized RCTs with at least
413 one year of follow-up reporting the incidence of side effects from available
414 anti-myopia interventions. Our findings indicate that the incidence of adverse events
415 associated with orthokeratology is 20.6 per 100 patient-years, while it was 19.3 per
416 100 patient-years for other contact lens. Complications linked to contact lens usage
417 included ocular noninfectious inflammatory events and sight-threatening microbial
418 keratitis.^{90, 94-96} A retrospective study authorized and approved by the US FDA
419 estimated the incidence of microbial keratitis from orthokeratology in children to be
420 14 per 10,000 patient-years (95% CI, 1.7-50.4 per 10,000 patient-years).⁹⁷ Atropine,
421 even at low concentrations of 0.01%, may lead to pupil dilation and loss of
422 accommodation, with photophobia, reduced near vision, and allergic conjunctivitis
423 being commonly reported ocular side effects.^{98, 99} Spectacles in comparison are a
424 more well-tolerated method for correcting and controlling myopia; however, they are
425 associated with a low risk of falls and bicycle collisions.^{51, 100} In this review, RLRL
426 therapy had a comparable incidence of side effects with spectacles.

427

428 This systematic review provides the first comprehensive evidence on the safety profile
429 and the risk-to-benefit ratio of RLRL therapy for myopia control. However, the results

430 should be interpreted within the context of several limitations. Firstly, most studies
431 lasted for 12 months, with only 11 children undergoing 24-month treatment in one
432 post-trial study included thereby limiting long-term evidence. There is a need for
433 further large-scale studies to thoroughly assess the long-term safety of RLRL therapy
434 in children and adolescents. Secondly, visual function in the included studies was
435 primarily evaluated using visual acuity, which could be influenced by subjective
436 factors. Objective assessments, such as multifocal electroretinography or
437 microperimetry, are necessary to provide more comprehensive safety evidence for
438 RLRL therapy. Thirdly, the methodology for reporting adverse events varied widely
439 across studies. Some studies documented the number of patients experiencing side
440 effects, whereas others detailed the number of adverse events. Fourthly, the accuracy
441 of Bullimore's model is dependent on the validity of its assumptions.¹⁶ It presumes
442 that the risk of vision loss from RLRL therapy is independent of refractive error. The
443 model also assumes a fixed treatment effect with myopia control. Fifthly, quality
444 appraisal was employed exclusively for the included RCTs, as the Cochrane Risk of
445 Bias Tool is not designed for use with non-randomized controlled trial, post-trial study,
446 retrospective study, single-arm study or case report. Finally, eleven of the twenty
447 studies were RCTs, which were conducted under strict surveillance. Such studies may
448 not accurately reflect real-world vision care, therefore more real-world studies are
449 needed to better understand long-term safety of RLRL in a greater variety of settings.

450

451 **Conclusion**

452 In conclusion, no irreversible visual function loss or ocular structural damage
453 associated with RLRL therapy was identified in this review. Meticulous supervision is
454 crucial throughout the entire treatment process by clinicians and parents, including
455 documenting the status of retina through fundus photography and OCT before
456 initiating RLRL therapy and at each routine examination, as well as tracking visual
457 acuity and the duration of any afterimages at home. Screening for and early
458 identification of rare super-responders is also important to avoid potential light injury.
459 Future larger and longer-term real-world studies are needed to better understand the

460 long-term safety of RLRL.

461

462 **Acknowledgment**

463 The authors thank the Hainan Province Clinical Medical Center, the National Natural
464 Science Foundation of China (82371086) for their support.

465

466 **Author Contributions:**

467 Prof. Wang had full access to all the data in the study and took responsibility for the
468 integrity of the data and the accuracy of the data analysis.

469 Study concept and design: Chen, Congdon, Wang.

470 Data collection: Chen, Chen, Xiong, Yang, Wang.

471 Analysis and interpretation of data: Chen, Wang.

472 Drafting of the manuscript: Chen, Congdon, Wang.

473 Critical revision of the manuscript for important intellectual content: All authors.

474 Statistical analysis: Chen, Wang.

475 Obtained funding: Wang.

476 Administrative, technical, or material support: Congdon, Wang.

477 Overall supervision: Wang.

478 **References:**

- 479 1. Holden BA, Fricke TR, Wilson DA, et al. Global Prevalence of Myopia and High
480 Myopia and Temporal Trends from 2000 through 2050. *Ophthalmology*
481 2016;123(5):1036-42.
- 482 2. Bullimore MA, Brennan NA. Myopia Control: Why Each Diopter Matters.
483 *Optom Vis Sci* 2019;96(6):463-5.
- 484 3. Ikuno Y. Overview of the Complications of High Myopia. *Retina*
485 2017;37(12):2347-51.
- 486 4. Mitchell P, Hourihan F, Sandbach J, Jin Wang J. The relationship between
487 glaucoma and myopia. *Ophthalmology* 1999;106(10):2010-5.
- 488 5. Sankaridurg P, Berntsen DA, Bullimore MA, et al. IMI 2023 Digest. *Invest*
489 *Ophthalmol Vis Sci* 2023;64(6):7.
- 490 6. ANSI. American National Standard for Safe Use of Lasers (ANSI Z80.36). The
491 Laser Institute of America. ANSI Z80.36-2021.
- 492 7. Xiong R, Zhu Z, Jiang Y, et al. Longitudinal Changes and Predictive Value of
493 Choroidal Thickness for Myopia Control after Repeated Low-Level Red-Light
494 Therapy. *Ophthalmology* 2023;130(3):286-96.
- 495 8. Jiang Y, Zhu Z, Tan X, et al. Effect of Repeated Low-Level Red-Light Therapy
496 for Myopia Control in Children: A Multicenter Randomized Controlled Trial.
497 *Ophthalmology* 2022;129(5):509-19.
- 498 9. Xiong R, Zhu Z, Jiang Y, et al. Sustained and rebound effect of repeated low-level
499 red-light therapy on myopia control: A 2-year post-trial follow-up study. *Clin Exp*
500 *Ophthalmol* 2022;50(9):1013-24.
- 501 10. He X, Wang J, Zhu Z, et al. Effect of Repeated Low-level Red Light on Myopia
502 Prevention Among Children in China With Premyopia: A Randomized Clinical Trial.
503 *JAMA Netw Open* 2023;6(4):e239612.
- 504 11. Dong J, Zhu Z, Xu H, He M. Myopia Control Effect of Repeated Low-Level
505 Red-Light Therapy in Chinese Children: A Randomized, Double-Blind, Controlled
506 Clinical Trial. *Ophthalmology* 2023;130(2):198-204.
- 507 12. Tang J, Liao Y, Yan N, et al. Efficacy of Repeated Low-Level Red-Light Therapy

508 for Slowing the Progression of Childhood Myopia: A Systematic Review and
509 Meta-analysis. *Am J Ophthalmol* 2023;252:153-63.

510 13. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an
511 updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71.

512 14. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool
513 for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928.

514 15. Gilbert CE, Lepvrier-Chomette N. Gender Inequalities in Surgery for Bilateral
515 Cataract among Children in Low-Income Countries: A Systematic Review.
516 *Ophthalmology* 2016;123(6):1245-51.

517 16. Bullimore MA, Ritchey ER, Shah S, et al. The Risks and Benefits of Myopia
518 Control. *Ophthalmology* 2021;128(11):1561-79.

519 17. Brennan NA, Toubouti YM, Cheng X, Bullimore MA. Efficacy in myopia control.
520 *Prog Retin Eye Res* 2021;83:100923.

521 18. Agresti A, Coull B. Approximate Is Better than "Exact" for Interval Estimation of
522 Binomial Proportions. *The American Statistician* 1998;52(2):119-26.

523 19. Wilson E. Probable Inference, the Law of Succession, and Statistical Inference.
524 *Journal of the American Statistical Association* 1927;22(158):209-12.

525 20. Jia S, Zhang N, Liu D, et al. Comparative Analysis of the Efficacy of
526 Low-Intensity Single-Wavelength Red Light Instrument and Acupuncture Therapy for
527 Preventing and Controlling Myopia in Adolescent Children. *Advances in Clinical*
528 *Medicine* 2022;12(12).

529 21. Jin X. Observation of the efficacy of repeated low-intensity red light irradiation
530 on the prevention and control of myopia in children and adolescents. *Chinese Science*
531 *and Technology Journal Database Medicine* 2023(7).

532 22. Lai W, Jia Y, Zhang Y, et al. Efficacy of low-level red light in young children
533 with high myopia. *Recent Advances in Ophthalmology* 2022;42(09):727-30.

534 23. Li E, Wang J, Huang H, et al. Efficacy of low-intensity red light on controlling
535 the refractive growth of myopia in adolescents. *Chinese Science and Technology*
536 *Journals Database Medicine and Health* 2022(10).

537 24. Ma G, Yan S, Zhao G, Wang K. Comparison of the effects of repeated

538 low-intensity red light irradiation and 0.01% atropine eye drops on the prevention and
539 control of myopia in children and adolescents. Chinese Journal of Eye Trauma and
540 Occupational Ophthalmology 2023;45(8).

541 25. Qiu K, Zhou L. Myopic Axial Length Change with Low-Intensity Laser Light
542 Therapy. Glass Enamel & Ophthalmic Optics 2021;49(09):17-22.

543 26. Wang W, Jiang Y, Zhu Z, et al. Axial Shortening in Myopic Children after
544 Repeated Low-Level Red-Light Therapy: Post Hoc Analysis of a Randomized Trial.
545 Ophthalmol Ther 2023;12(2):1223-37.

546 27. Xiong F, Mao T, Liao H, et al. Orthokeratology and Low-Intensity Laser Therapy
547 for Slowing the Progression of Myopia in Children. Biomed Res Int
548 2021;2021:8915867.

549 28. Xuan M, Zhu Z, Jiang Y, et al. Longitudinal Changes in Choroidal Structure
550 Following Repeated Low-Level Red-Light Therapy for Myopia Control: Secondary
551 Analysis of a Randomized Controlled Trial. Asia Pac J Ophthalmol (Phila)
552 2023;12(4):377-83.

553 29. Yang W, Lin F, Li M, et al. Immediate Effect in the Retina and Choroid after 650
554 nm Low-Level Red Light Therapy in Children. Ophthalmic Res 2023;66(1):312-8.

555 30. Zhou L, Qiu K, Tong L. The Analysis of Clinical Trial of Slowing the Progression
556 of Myopiain Children with Low Red Laser. Glass Enamel & Ophthalmic Optics
557 2022;50(1).

558 31. Zhou L, Xing C, Qiang W, et al. Low-intensity, long-wavelength red light slows
559 the progression of myopia in children: an Eastern China-based cohort. Ophthalmic
560 Physiol Opt 2022;42(2):335-44.

561 32. Zhu X. Analysis of the therapeutic effect of low energy red light on myopia in
562 children and adolescents. Chinese Science and Technology Journal Database
563 Medicine 2023(7).

564 33. Yan Y, Xue W, Zhao Y, et al. Effect of 650 nm semiconductor laser on juvenile
565 myopia control. Journal of Clinical Ophthalmology 2021;29(02):132-7.

566 34. Chen Y, Xiong R, Chen X, et al. Efficacy Comparison of Repeated Low-Level
567 Red Light and Low-Dose Atropine for Myopia Control: A Randomized Controlled

568 Trial. *Transl Vis Sci Technol* 2022;11(10):33.

569 35. Chen H, Wang W, Liao Y, et al. Low-intensity red-light therapy in slowing
570 myopic progression and the rebound effect after its cessation in Chinese children: a
571 randomized controlled trial. *Graefe's Archive for Clinical and Experimental*
572 *Ophthalmology* 2023;261(2):575-84.

573 36. Tian L, Cao K, Ma DL, et al. Investigation of the Efficacy and Safety of 650 nm
574 Low-Level Red Light for Myopia Control in Children: A Randomized Controlled
575 Trial. *Ophthalmol Ther* 2022;11(6):2259-70.

576 37. Zhou L, Tong L, Li Y, et al. Photobiomodulation therapy retarded axial length
577 growth in children with myopia: evidence from a 12-month randomized controlled
578 trial evidence. *Sci Rep* 2023;13(1):3321.

579 38. Zhou W, Liao Y, Wang W, et al. Efficacy of Different Powers of Low-Level Red
580 Light in Children for Myopia Control. *Ophthalmology* 2024;131(1):48-57.

581 39. Tian L, Cao K, Ma DL, et al. Six-month repeated irradiation of 650 nm low-level
582 red light reduces the risk of myopia in children: a randomized controlled trial. *Int*
583 *Ophthalmol* 2023;43(10):3549-58.

584 40. Liu Z, Sun Z, Du B, et al. The Effects of Repeated Low-Level Red-Light Therapy
585 on the Structure and Vasculature of the Choroid and Retina in Children with
586 Premyopia. *Ophthalmol Ther* 2024;13(3):739-59.

587 41. Lin ZH, Tao ZY, Kang ZF, Deng HW. A Study on the Effectiveness of 650-nm
588 Red-Light Feeding Instruments in the Control of Myopia. *Ophthalmic Research*
589 2023;66(1):664-71.

590 42. Zhao C, Ni Y, Zeng J. Effect of red-light therapy on retinal and choroidal blood
591 perfusion in myopic children. *Ophthalmic Physiol Opt* 2023;43(6):1427-37.

592 43. Xiong Y, Hu J, Gu C, Tang J. Influence of low-intensity red light therapy on
593 diopter changes, axial length and tear film rupture time in adolescent myopia patients.
594 *Journal of North Sichuan Medical College* 2024;39(01):100-3.

595 44. Zhang L, Guo Y, Chen J, et al. Clinical effect of 650-nm low-level red light in
596 conjunction with orthokeratology in myopia control. *Journal of Otolaryngology and*

597 Ophthalmology of Shandong University 2024;1-8.

598 45. Liu L, Wang Y, Liu F, et al. Effects of repeated low-level red-light therapy on
599 macular retinal thickness and microvascular system in children with myopia.
600 Photodiagnosis Photodyn Ther 2024;45:103938.

601 46. Wang W, Jiang Y, Zhu Z, et al. Clinically Significant Axial Shortening in Myopic
602 Children After Repeated Low-Level Red Light Therapy: A Retrospective Multicenter
603 Analysis. Ophthalmol Ther 2023;12(2):999-1011.

604 47. Liu H, Yang Y, Guo J, et al. Retinal Damage After Repeated Low-level Red-Light
605 Laser Exposure. JAMA Ophthalmology 2023.

606 48. Tian Y, Xiao Z. Recovery of retinal structural damage after repeated low-intensity
607 red light therapy for high myopia: a case report. Chinese Journal of Experimental
608 Ophthalmology 2023;41(9):853-5.

609 49. Gwiazda J, Hyman L, Hussein M, et al. A randomized clinical trial of progressive
610 addition lenses versus single vision lenses on the progression of myopia in children.
611 Invest Ophthalmol Vis Sci 2003;44(4):1492-500.

612 50. Cheng D, Schmid KL, Woo GC, Drobe B. Randomized Trial of Effect of Bifocal
613 and Prismatic Bifocal Spectacles on Myopic Progression Two-Year Results. Arch
614 Ophthalmol 2010 128(1):12-9.

615 51. Sankaridurg P, Donovan L, Varnas S, et al. Spectacle lenses designed to reduce
616 progression of myopia: 12-month results. Optom Vis Sci 2010;87(9):631-41.

617 52. Correction of Myopia Evaluation Trial 2 Study Group for the Pediatric Eye
618 Disease Investigator G. Progressive-addition lenses versus single-vision lenses for
619 slowing progression of myopia in children with high accommodative lag and near
620 esophoria. Invest Ophthalmol Vis Sci 2011;52(5):2749-57.

621 53. Hasebe S, Jun J, Varnas S. Myopia Control with Positively-Aspherized
622 Progressive 2 Addition Lenses- A Two-year, Multicenter, Randomized,
623 Controlled Trial. Invest Ophthalmol Vis Sci 2014

624 54. Kanda H, Oshika T, Hiraoka T, et al. Effect of spectacle lenses designed to reduce
625 relative peripheral hyperopia on myopia progression in Japanese children: a 2-year
626 multicenter randomized controlled trial. Jpn J Ophthalmol 2018;62(5):537-43.

- 627 55. Lam CSY, Tang WC, Tse DY, et al. Defocus Incorporated Multiple Segments
628 (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial.
629 Br J Ophthalmol 2020;104(3):363-8.
- 630 56. Bao J, Yang A, Huang Y, et al. One-year myopia control efficacy of spectacle
631 lenses with aspherical lenslets. Br J Ophthalmol 2022;106(8):1171-6.
- 632 57. Bao J, Huang Y, Li X, et al. Spectacle Lenses With Aspherical Lenslets for
633 Myopia Control vs Single-Vision Spectacle Lenses: A Randomized Clinical Trial.
634 JAMA Ophthalmol 2022;140(5):472-8.
- 635 58. Liu X, Wang P, Xie Z, et al. One-year myopia control efficacy of cylindrical
636 annular refractive element spectacle lenses. Acta Ophthalmol 2023;101(6):651-7.
- 637 59. Rappon J, Chung C, Young G, et al. Control of myopia using diffusion optics
638 spectacle lenses: 12-month results of a randomised controlled, efficacy and safety
639 study (CYPRESS). Br J Ophthalmol 2023;107(11):1709-15.
- 640 60. Yen M, Liu J, Kao S, Shiao C. Comparison of the effect of atropine and
641 cyclopentolate on myopia. Ann Ophthalmol 1989;21(5):180-7.
- 642 61. Shih YF, Chen CH, Chou AC, et al. Effects of different concentrations of atropine
643 on controlling myopia in myopic children. JOURNAL OF OCULAR
644 PHARMACOLOGY AND THERAPEUTICS 1999;15(1):85-90.
- 645 62. Chua WH, Balakrishnan V, Chan YH, et al. Atropine for the treatment of
646 childhood myopia. Ophthalmology 2006;113(12):2285-91.
- 647 63. Chia A, Chua WH, Cheung YB, et al. Atropine for the treatment of childhood
648 myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the
649 Treatment of Myopia 2). Ophthalmology 2012;119(2):347-54.
- 650 64. Yi S, Huang Y, Yu S, et al. Therapeutic effect of atropine 1% in children with low
651 myopia. J AAPOS 2016;20(4):379.
- 652 65. Wang YR, Bian HL, Wang Q. Atropine 0.5% eyedrops for the treatment of
653 children with low myopia: A randomized controlled trial. Medicine (Baltimore)
654 2017;96(27):e7371.
- 655 66. Yam JC, Jiang Y, Tang SM, et al. Low-Concentration Atropine for Myopia
656 Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled

657 Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control.
658 *Ophthalmology* 2019;126(1):113-24.

659 67. Wei S, Li SM, An W, et al. Safety and Efficacy of Low-Dose Atropine Eyedrops
660 for the Treatment of Myopia Progression in Chinese Children: A Randomized Clinical
661 Trial. *JAMA Ophthalmol* 2020;138(11):1178-84.

662 68. Yam JC, Li FF, Zhang X, et al. Two-Year Clinical Trial of the Low-Concentration
663 Atropine for Myopia Progression (LAMP) Study: Phase 2 Report. *Ophthalmology*
664 2020;127(7):910-9.

665 69. Cui C, Li X, Lyu Y, et al. Safety and efficacy of 0.02% and 0.01% atropine on
666 controlling myopia progression: a 2-year clinical trial. *Sci Rep* 2021;11(1):22267.

667 70. Hieda O, Hiraoka T, Fujikado T, et al. Efficacy and safety of 0.01% atropine for
668 prevention of childhood myopia in a 2-year randomized placebo-controlled study. *Jpn*
669 *J Ophthalmol* 2021;65(3):315-25.

670 71. Saxena R, Dhiman R, Gupta V, et al. Atropine for the Treatment of Childhood
671 Myopia in India: Multicentric Randomized Trial. *Ophthalmology*
672 2021;128(9):1367-9.

673 72. Lee SS, Lingham G, Blaszkowska M, et al. Low-concentration atropine eyedrops
674 for myopia control in a multi-racial cohort of Australian children: A randomised
675 clinical trial. *Clin Exp Ophthalmol* 2022;50(9):1001-12.

676 73. Yam JC, Zhang XJ, Zhang Y, et al. Three-Year Clinical Trial of
677 Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued
678 Versus Washout: Phase 3 Report. *Ophthalmology* 2022;129(3):308-21.

679 74. Chia A, Ngo C, Choudry N, et al. Atropine Ophthalmic Solution to Reduce
680 Myopia Progression in Pediatric Subjects: The Randomized, Double-Blind
681 Multicenter Phase II APPLE Study. *Asia Pac J Ophthalmol (Phila)* 2023;12(4):370-6.

682 75. Hansen NC, Hvid-Hansen A, Moller F, et al. Safety and efficacy of 0.01% and 0.1%
683 low-dose atropine eye drop regimens for reduction of myopia progression in Danish
684 children: a randomized clinical trial examining one-year effect and safety. *BMC*
685 *Ophthalmol* 2023;23(1):438.

686 76. Moriche-Carretero M, Revilla-Amores R, Gutierrez-Blanco A, et al. Five-year

687 results of atropine 0.01% efficacy in the myopia control in a European population. Br
688 J Ophthalmol 2023.

689 77. Xu S, Li Z, Zhao W, et al. Effect of atropine, orthokeratology and combined
690 treatments for myopia control: a 2-year stratified randomised clinical trial. Br J
691 Ophthalmol 2023;107(12):1812-7.

692 78. Yam JC, Zhang XJ, Zhang Y, et al. Effect of Low-Concentration Atropine
693 Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized
694 Clinical Trial. JAMA 2023;329(6):472-81.

695 79. Cho P, Cheung SW. Retardation of myopia in Orthokeratology (ROMIO) study: a
696 2-year randomized clinical trial. Invest Ophthalmol Vis Sci 2012;53(11):7077-85.

697 80. Charm J, Cho P. High Myopia–Partial Reduction Ortho-k A 2-Year Randomized
698 Study. Optom Vis Sci 2013.

699 81. Kinoshita N, Konno Y, Hamada N, et al. Efficacy of combined orthokeratology
700 and 0.01% atropine solution for slowing axial elongation in children with myopia: a
701 2-year randomised trial. Sci Rep 2020;10(1):12750.

702 82. Tan Q, Ng AL, Choy BN, et al. One-year results of 0.01% atropine with
703 orthokeratology (AOK) study: a randomised clinical trial. Ophthalmic Physiol Opt
704 2020;40(5):557-66.

705 83. Guo B, Cheung SW, Kojima R, Cho P. One-year results of the Variation of
706 Orthokeratology Lens Treatment Zone (VOLTZ) Study: a prospective randomised
707 clinical trial. Ophthalmic Physiol Opt 2021;41(4):702-14.

708 84. Jakobsen TM, Moller F. Control of myopia using orthokeratology lenses in
709 Scandinavian children aged 6 to 12 years. Eighteen-month data from the Danish
710 Randomized Study: Clinical study Of Near-sightedness; Treatment with
711 Orthokeratology Lenses (CONTROL study). Acta Ophthalmol 2022;100(2):175-82.

712 85. Walline JJ, Jones L, Mutti DO, Zadnik K. A randomized trial of the effects of
713 rigid contact lenses on myopia progression. Arch Ophthalmol 2004

714 86. Cheng X, Xu J, Chehab K, et al. Soft Contact Lenses with Positive Spherical
715 Aberration for Myopia Control. Optom Vis Sci 2016;93(4):353-66.

716 87. Chamberlain P, Peixoto-de-Matos SC, Logan NS, et al. A 3-year Randomized

717 Clinical Trial of MiSight Lenses for Myopia Control. *Optom Vis Sci*
718 2019;96(8):556-67.

719 88. Walline JJ, Walker MK, Mutti DO, et al. Effect of High Add Power, Medium Add
720 Power, or Single-Vision Contact Lenses on Myopia Progression in Children: The
721 BLINK Randomized Clinical Trial. *JAMA* 2020;324(6):571-80.

722 89. Garcia-Del Valle AM, Blazquez V, Gros-Otero J, et al. Efficacy and safety of a
723 soft contact lens to control myopia progression. *Clin Exp Optom* 2021;104(1):14-21.

724 90. Gaume Giannoni A, Robich M, Berntsen DA, et al. Ocular and Nonocular
725 Adverse Events during 3 Years of Soft Contact Lens Wear in Children. *Optom Vis Sci*
726 2022;99(6):505-12.

727 91. Shimojo S, Kamitani Y, Nishida S. Afterimage of perceptually filled-in surface.
728 *Science* 2001;293(5535):1677-80.

729 92. Expert workgroup of expert consensus on repeated low-level red-light as an
730 alternative treatment for childhood myopia. Expert consensus on repeated low-level
731 red-light as an alternative treatment for childhood myopia (2022). *Chinese Journal of*
732 *Experimental Ophthalmology* 2022;40(7):599-603.

733 93. Stapleton F, Keay L, Edwards K, et al. The incidence of contact lens-related
734 microbial keratitis in Australia. *Ophthalmology* 2008;115(10):1655-62.

735 94. Cheng X, Brennan NA, Toubouti Y, Greenaway NL. Safety of soft contact lenses
736 in children: retrospective review of six randomized controlled trials of myopia control.
737 *Acta Ophthalmol* 2020;98(3):e346-e51.

738 95. Stapleton F. Contact lens-related corneal infection in Australia. *Clinical and*
739 *Experimental Optometry* 2021;103(4):408-17.

740 96. Szczotka-Flynn LB, Shovlin JP, Schnider CM, et al. American Academy of
741 Optometry Microbial Keratitis Think Tank. *Optom Vis Sci* 2021;98(3):182-98.

742 97. Bullimore MA, Sinnott LT, Jones-Jordan LA. The risk of microbial keratitis with
743 overnight corneal reshaping lenses. *Optom Vis Sci* 2013;90(9):937-44.


744 98. Ha A, Kim SJ, Shim SR, et al. Efficacy and Safety of 8 Atropine Concentrations
745 for Myopia Control in Children: A Network Meta-Analysis. *Ophthalmology*
746 2022;129(3):322-33.

- 747 99. Gong Q, Janowski M, Luo M, et al. Efficacy and Adverse Effects of Atropine in
748 Childhood Myopia: A Meta-analysis. *JAMA Ophthalmol* 2017;135(6):624-30.
- 749 100. Zhang M, Congdon N, Li L, et al. Myopia, spectacle wear, and risk of bicycle
750 accidents among rural Chinese secondary school students: the Xichang Pediatric
751 Refractive Error Study report no. 7. *Arch Ophthalmol* 2009;127(6):776-83.
- 752
- 753

754 **Figure Legends**

755

756 **Figure 1.** Study selection outlined according to Preferred Reporting Items for
757 Systematic Reviews and Meta-Analyses (PRISMA) guidelines. RCT=randomized
758 controlled trial.



759

760

761 **Figure 2.** Risk of bias assessment by Cochrane Risk of Bias Tool of the included
 762 RCTs. RCT=randomized controlled trial.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Chen (a) et al 2022	+	+	-	+	+	+	+
Chen (b) et al 2022	+	?	-	+	+	+	?
Dong et al 2022	+	+	+	+	+	+	+
He et al 2023	+	+	-	+	+	+	+
Jiang et al 2021	+	+	-	+	+	+	+
Liu (a) et al 2024	+	?	-	+	+	?	?
Tian (a) et al 2023	+	?	-	+	+	?	+
Tian et al 2022	+	?	-	+	+	?	+
Yan et al 2021	+	?	-	+	+	+	+
Zhou (a) et al 2023	+	+	-	+	+	?	+
Zhou (b) et al 2023	+	?	-	+	+	?	+

763

Table 1. Characteristics of included studies.

No. of Patients by Study (Study Type)	Treatment	Age (y)	Female (%)	Mean SER (D)	Mean AL (mm)	Completion Rate (%)
Jiang et al 2021 (RCT) ⁸						
117	Intervention (RLRL)	8-13	62 (52.1)	-2.49 (0.92)	24.5 (0.67)	98.3
129	Control (SVS)	8-13	72 (49.7)	-2.67 (1.06)	24.6 (0.86)	89.0
Yan et al 2021 (RCT) ³³						
60	Intervention (RLRL)	7-12	58 (48.3)	-2.52 (1.15)	24.2 (0.92)	100
60	Control (SVS)	7-12		-2.53 (1.15)	24.4 (0.79)	100
Xiong et al 2022 (post-trial follow-up study) ⁹						
11	RLRL-RLRL	8-13	4 (36.4)	-1.77 (0.57)	24.9 (0.94)	-
10	SVS-RLRL	8-13	5 (50.0)	-2.57 (1.11)	24.8 (0.71)	-
52	RLRL-SVS	8-13	26 (50.0)	-2.50 (0.83)	24.5 (0.58)	-
41	SVS-SVS	8-13	26 (63.4)	-2.76 (1.15)	24.6 (0.94)	-
Dong et al 2022 (RCT) ¹¹						
56	Intervention (RLRL)	7-12	30 (53.6)	-3.13 (1.91)	24.7 (1.04)	94.6
55	Control (Sham device)	7-12	26 (46.4)	-2.82 (1.86)	24.6 (0.96)	98.2
Chen (a) et al 2022 (RCT) ³⁴						
30	Intervention (RLRL)	7-15	17 (54.8)	-2.60 (1.17)	24.5 (0.79)	96.8
30	Control (0.01% atropine)	7-15	14 (45.2)	-2.59 (1.24)	24.7 (0.98)	96.8

Chen (b) et al 2022 (RCT) ³⁵						
46	Intervention (RLRL)	6-13	19 (41.3)	-2.54 (1.04)	24.6 (0.97)	90.2
40	Control (SVS)	6-13	15 (37.5)	-2.29 (0.77)	24.6 (0.76)	78.4
Tian et al 2022 (RCT) ³⁶						
91	Intervention (RLRL)	6-12	55 (49.1)	-2.00 (0.33)	24.3 (0.92)	81.3
88	Control (SVS)	6-12	57 (50.9)	-2.00 (0.25)	24.2 (0.85)	78.6
He et al 2023 (RCT) ¹⁰						
126	Intervention (RLRL)	6-11	68 (48.9)	0.14 (0.30)	23.4 (0.68)	90.7
122	Control (SVS)	6-11	71 (51.1)	0.16 (0.28)	23.3 (0.69)	87.8
Zhou (a) et al 2023 (RCT) ³⁷						
20	Intervention (RLRL)	3-16	9 (37.5)	-2.93 (1.87)	24.6 (1.16)	96.0
15	Control (SVS)	3-16	7 (41.2)	-2.11 (1.21)	24.4 (0.87)	76.0
Zhou (b) et al 2023 (RCT) ³⁸						
43	Intervention (RLRL 0.37mW)	6-15	20 (40.0)	-1.72 (0.91)	24.2 (0.79)	86.0
47	Intervention (RLRL 0.60mW)	6-15	25 (50.0)	-2.01 (0.87)	24.1 (0.88)	94.0
44	Intervention (RLRL 1.20mW)	6-15	24 (48.0)	-2.08 (1.33)	24.5 (0.91)	88.0
43	Control (SVS)	6-15	21 (42.0)	-2.10 (0.90)	24.4 (0.90)	86.0
Tian (a) et al 2023 (RCT) ³⁹						
56	Intervention (RLRL)	6-12	33 (58.9)	0.25 (0.25)	23.1 (0.80)	100
56	Control (SVS)	6-12	31 (55.4)	0.25 (0.19)	23.1 (0.70)	100
Lin et al 2023 (non-randomized controlled trial) ⁴¹						

41	Intervention (RLRL)	6-18	84 (51.2)	-3.20 (2.82)	24.3 (1.04)	58.6
58	Intervention (RLRL)	6-18		-7.93 (2.95)	25.7 (1.57)	82.9
65	Control (SVS)	6-18		-2.32 (2.64)	24.3 (1.21)	92.9
Zhao et al 2023 (non-randomized controlled trial) ⁴²						
47	Intervention (RLRL)	6-18	18 (38.3)	-2.31 (1.26)	24.6 (0.88)	100
20	Control (SVS)	6-18	8 (40.0)	-2.75 (0.84)	24.8 (0.90)	100
Wang et al 2023 (retrospective study) ⁴⁶						
434	Intervention (RLRL)	3-17	200 (46.1)	-3.74 (2.60)	24.9 (1.20)	-
Liu et al 2023 & Tian (b) et al 2023 (case report) ^{47,48}						
1	Intervention (RLRL)	12	1 (100)	OD -6.75D OS -6.25D	-	-
Liu (a) et al 2024 (RCT) ⁴⁰						
47	Intervention (RLRL)	7-12	19 (44.2)	0.17 (0.35)	23.6 (0.78)	91.5
47	Control (SVS)	7-12	20 (47.6)	0.30 (0.35)	23.3 (0.73)	89.4
Liu (b) et al 2024 (single-arm study) ⁴⁵						
40	Intervention (RLRL)	7-14	17 (42.5)	-2.75 (1.43)	24.9 (0.97)	100
Xiong et al 2024 (non-randomized controlled trial) ⁴³						
45	Intervention (RLRL)	7-16	22 (48.9)	-3.00 (0.90)	23.6 (0.35)	100
45	Control (SVS)	7-16	23 (51.1)	-3.02 (0.11)	23.6 (0.37)	100
Zhang et al 2024 (non-randomized controlled trial)* ⁴⁴						
44	Intervention (RLRL)	≥7	25 (56.8)	-1.87 (1.16)	24.1 (0.80)	100

32	Intervention (OK)	≥ 7	14 (43.8)	-2.44 (1.15)	24.2 (0.73)	100
29	Intervention (RLRL+OK)	≥ 7	10 (34.5)	-2.55 (1.32)	24.5 (0.96)	100
36	Control (SVS)	≥ 7	18 (50.0)	-2.11 (1.11)	24.3 (0.82)	100

* Only eye number for each group and total participant number was available in the publication.

Data were presented as number (percentage) or mean (standard deviation).

RLRL=repeated low-level red-light; SVS=single vision spectacles; RCT=randomized controlled trial; SER= spherical equivalent refraction; AL=axial length; OK=orthokeratology.

Table 2. Visual function, ocular structures and adverse events reported in RLRL studies.

Study	Follow-up (mo)	Visual function outcome	Ocular Structural Outcome	Adverse events
Jiang et al 2021 ⁸	12	108 (97.3%) participants achieved BCVA of 20/20, and the BCVA in the remaining 3 (2.7%) participants was 20/25. *	No structural damage on photosensory layer was identified by OCT. (n=72)	<ul style="list-style-type: none"> • No adverse events were reported, including glare, flash blindness, or afterimages. • No severe adverse events developed, including sudden vision loss by 2 lines occurring in a period of a few second/s or minutes to a few days or scotoma.
Yan et al 2021 ³³	12	-	-	<ul style="list-style-type: none"> • No ocular adverse events were reported, including conjunctival hyperemia, edema, photophobia, tears, corneal epithelial damage, lens opacity, macular damage. • No cognitive impairment and behavioral abnormalities were found.
Xiong et al 2022 ⁹	12	10 (100%) participants maintained BCVA of 20/20.	No structural damage on photosensory layer was identified by OCT.	<ul style="list-style-type: none"> • No severe adverse events or side effects including sudden vision loss of more than two lines, scotoma, dazzling, short-term glare, flash blindness, and afterimages developed.
Xiong et al 2022 ⁹	24	11 (100%) participants maintained	No structural damage on	No severe adverse events or side effects

		BCVA of 20/20.	photosensory layer was identified by OCT.	including sudden vision loss of more than two lines, scotoma, dazzling, short-term glare, flash blindness, and afterimages developed.
Dong et al 2022 ¹¹	6	-	-	18 adverse events were reported in 13 participants, but none were related to RLRL therapy. †
Chen (a) et al 2022 ³⁴	12	58 eyes (100%) maintained BCVA of 20/20.	No structural damage was identified by OCT.	<ul style="list-style-type: none"> • No severe adverse events were reported, including blindness, death, hospitalization, or conditions requiring medical or surgical interventions. • No adverse events including a sudden vision loss of two lines or more, a scotoma, photophobia, allergy, dry mouth, or tachycardia developed. • 1 participant reported dizziness after the red-light therapy, but the symptoms resolved after a few minutes and only occurred in the immediate post-treatment period for a few days.
Chen (b) et al 2022 ³⁵	12	BCVA remained normal at each follow-up visit.	No structural damage including vitreomacular traction, macular schisis,	No adverse events including dazzling, glare, long-term afterimages, and flash blindness were reported.

			macular hole, intraretinal fluid, subretinal fluid, hemorrhage, retinal pigment epithelium proliferation, and atrophy was identified by OCT.	
Tian et al 2022 ³⁶	6	-	-	No adverse events including photophobia, eye itching, burning sensation, dry eye, blurred vision, glare, dazzling, keratitis, and conjunctivitis were reported.
He et al 2023 ¹⁰	12	123 (100%) participants achieved BCVA of 20/25.	No structural damage including vitreomacular traction, macular schisis, macular hole, intraretinal fluid, subretinal fluid, hemorrhage, retinal pigment epithelium proliferation, and atrophy was identified by OCT.	No adverse event was reported, including glare, flash blindness, or afterimages longer than 6 minutes after treatment. ††
Zhou (a) et al 2023 ³⁷	12	No BCVA indicated visual function loss.	No structural damage was identified by OCT.	• Reversible subjective symptoms without objective ocular abnormalities (CTCAE grade 1) ‡, including reversible vision

				<p>loss lasting 2.1 ± 0.7 min (n=23) after red-light therapy due to flash blindness or glare with afterimage, and afterimage with an average of 3.2 ± 1.2 min.</p> <ul style="list-style-type: none"> • No dry eye, cataract, keratitis, night blindness, photophobia or any other permanent visual impairment. • No systemic adverse effects (such as headache or dizziness), severe adverse events, or other adverse events related to grades of ocular diseases: Grade 2–5 of CTCAE.
Zhou (b) et al 2023 ³⁸	6	BCVA remained normal at each follow-up visit.	No retinal or choroidal structural abnormalities were identified by OCT.	No adverse events were reported.
Tian (a) et al 2023 ³⁹	6	-	-	No adverse events were reported.
Lin et al 2023 ⁴¹	2	-	-	<ul style="list-style-type: none"> • Afterimage is the most common phenomenon post RLRL therapy, which can be alleviated by a short period of eye-closing and rest; with the progression of treatment, this phenomenon does not appear to worsen.

				· No adverse events were reported.
Zhao et al 2023 ⁴²	1	-	No retinal structure related photodamage was identified by OCT.	-
Wang et al 2023 ⁴⁶	At least 12	-	-	No adverse events were reported.
Liu et al & Tian (b) et al 2023 ^{47,48}	5	<ul style="list-style-type: none"> · Binocular BCVA declined from 20/20 to 20/30. § · Multifocal electroretinogram revealed the response of the central macula (ring 1) was moderately decreased and the response of paramacula (ring 2 and 3) was mildly decreased in both eyes. 	<ul style="list-style-type: none"> · Bilateral foveal ellipsoid zone disruption and interdigitation zone discontinuity were identified by OCT. § · Fundus photographs revealed bilaterally darkened foveae with a hypoautofluorescent plaque in autofluorescence images. 	Prolonged afterimages after light therapy (occasionally exceeding 8 minutes).
Liu (a) et al 2024 ⁴⁰	12	No BCVA indicated visual function loss.	No structural damage was identified by OCT.	No adverse events were reported.
Liu (b) et al 2024 ⁴⁵	6	-	No change in macular structure or microcirculatory system was identified by OCT and OCTA.	No adverse events were reported.
Xiong et al 2024 ⁴³	6	-	No ocular surface damage	No adverse events were reported.

			was found, and no structural damage or macular hemorrhage was identified by OCT.	
Zhang et al 2024 ⁴⁴	6	BCVA remained unchanged at each follow-up visit compared to baseline.	No structural damage within 6mm macular region was identified by OCT.	No adverse events were reported.

RLRL=repeated low-level red-light therapy; mo=month; BCVA=best corrected visual acuity; OCT=optical coherence tomography.

*In the SVS control arm, the proportion of compromised BCVA 20/25 was 8 of 112 (7.1%).

†18 adverse events included one case each of influenza, an eyelid injury requiring surgical repair, and acute mesenteric lymphadenitis; two cases each of earwax blockage, and allergic rhinitis; and three cases of dental caries.

††Two participants dropped out due to the afterimage duration exceeded 6 minutes at baseline.

‡Common Terminology Criteria for Adverse Events (CTCAE) grade 1 refers to mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.

§After 3 months without RLRL therapy, the bilateral outer retinal damage partially recovered, and the visual acuity improved to 20/25 in both eyes. After 4 months discontinued RLRL therapy, the bilateral outer retinal damage totally recovered.

Table 3. Estimated NNH and NNH/NNT ratios associated with RLRL therapy.

Variable	Multiplier	Value*
Annual incidence of vision loss		8.77
Years of vision loss accrued	× 65 years	570
NNH†		
For 1 year of vision loss	10,000/years vision loss	17.5
For 5 years of vision loss	5 × 10,000/years vision loss	87.7

* We assumed that the annual incidence of vision loss from RLRL therapy as 8.77 per 10,000 patient-years. Any vision loss is estimated to be experienced for 65 years after the event.

† The NNH/NNT ratios are 12.7-fold for -3D, 14.4-fold for -4D, 16.4-fold for -5D, 18.1-fold for -6D, 19.9-fold for -7D and 21.4-fold for -8D with RLRL therapy.

All values are presented per 10,000 patients.

RLRL=repeated low-level red-light; NNH=number needed to harm; NNT=number needed to treat.

Table 4. Comparison of the ocular adverse event incidence rate between RLRL and other interventions.

Interventions	Baseline age criteria (years)	Number of participants	Person- years	Ocular adverse events	Ocular adverse events per 100 patient-years	95% CI*
RLRL ^{8-11,33-48}	3-18	1436	1139.8	1	0.088	0.02-0.50
Low-dose atropine ⁶⁰⁻⁷⁸	4-16	2736	5368	393	7.32	6.65-8.05
Orthokeratology ^{76,79-84}	6-12	231	364.5	75	20.6	16.7-25.0
Anti-myopia contact lens ⁸⁵⁻⁹⁰	7-15	697	1899	366	19.3	17.6-21.1
Spectacles designed for myopia reduction ⁴⁹⁻⁵⁹	6-16	1247	2299	5	0.22	0.09-0.51

RLRL=repeated low-level red-light; CI=confidence interval.

Anti-myopia contact lens includes rigid gas permeable contact lens and soft multifocal contact lens. Spectacles designed for myopia reduction includes bifocal lens, progressive addition spectacles, aspherical lenslets and peripheral defocus spectacles.

*95% CI was calculated using Wilson methods.